MR Guided Focused Ultrasound Surgery of Metastatic Bone Tumors

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
InSightec
ClinicalTrials.gov Identifier:
NCT00350233
First received: July 6, 2006
Last updated: September 13, 2012
Last verified: September 2012

July 6, 2006
September 13, 2012
May 2006
February 2010   (final data collection date for primary outcome measure)
Determine safety of MRgFUS of Bone Metastases [ Time Frame: Within 1 month of Treatment ] [ Designated as safety issue: No ]
Not Provided
Complete list of historical versions of study NCT00350233 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
MR Guided Focused Ultrasound Surgery of Metastatic Bone Tumors
MR Guided Focused Ultrasound Surgery of Metastatic Bone Tumors

The objective of this trial is to evaluate the safety and effectiveness of MRgFUS in the treatment of metastatic bone tumors.

Bone is the third most common organ involved by metastasic disease behind lung and liver. In breast cancer, bone is the second most common site of metastatic spread, and 90% of patients dying of breast cancer have bone metastasis. Breast and prostate cancer metastasize to bone most frequently, which reflects the high incidence of both these tumors, as well as their prolonged clinical courses.

Post cancer survival has increased with improvement in early detection and treatments. As a consequence, the number of patients developing metastatic bone disease during their lifetime has also increased. Patients with bone metastasis from breast cancer have an average 2-year survival from the time of presentation with their first bone lesion. In patients who die from breast, prostate, and lung cancer, autopsy studies have shown that up to 85% have evidence of bone metastases at the time of death.

Current treatments for patients with bone metastases are primarily palliative and include localized therapies (radiation and surgery), systemic therapies (chemotherapy, hormonal therapy, radiopharmaceutical, and bisphosphanates), and analgesics (opioids and non-steroidal anti-inflammatory drugs). Recently, radiofrequency ablation has been tested as a treatment option for bone metastases. The main goals of these treatments are improvement of quality of life and functional level. These goals can be further described: 1) Pain relief, 2) Preservation and restoration of function, 3) Local tumor control, 4) Skeletal stabilization.

The study hypothesis is that MRgFUS is a safe and potentially effective non-invasive treatment for metastatic bone tumors with a low incidence of co-morbidity. Based on the result of this study the Sponsor will initiate a larger study in an effort to approve metastatic bone tumors as an indication for its MRgFUS ExAblate device.

Interventional
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Bone Metastases
Device: ExAblate 2000
Experimental: ExAblate MRgFUS
Intervention: Device: ExAblate 2000
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
10
February 2010
February 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Men and women age 18 and older
  2. Patients who are able and willing to give consent and able to attend all study visits
  3. Patients with histologically or cytologically confirmed malignant disease with a bone lesion that appears to be metastatic disease by clinical and or imaging techniques
  4. Must have persistent pain from at least one site of bone metastases

    • Patient with VAS pain score ≥ 4, when VAS test taken without medication, OR
    • Patient taking pain-relieving medication for management of bone metastases.
  5. Targeted tumor(s) are ExAblate device accessible
  6. Targeted tumor(s) size is smaller than 8 cm in diameter
  7. Patient whose lesion is on bone and is ≥ 10-mm from the skin.
  8. Tumor(s) clearly visible by non-contrast MRI
  9. Able to communicate sensations during the MRgFUS ExAblate treatment
  10. At least 2 weeks since chemotherapy
  11. At least 1 month since radiation therapy

Exclusion Criteria:

  1. Diffuse skeletal tumoral spread as evaluated by imaging.
  2. Patients who need pre-treatment surgical stabilization of the affected bony structure.
  3. Targeted tumor is in weight bearing bones or impending fracture
  4. Targeted tumor is in the vertebral column.
  5. Patients with unstable cardiac status including:

    • Unstable angina pectoris on medication
    • Patients with documented myocardial infarction within six months of protocol entry
    • Congestive heart failure requiring medication (other than diuretic)
    • Patients on anti-arrhythmic drugs
  6. Severe hypertension (diastolic BP > 100 on medication)
  7. Patients with standard contraindications for MR imaging such as non-MRI compatible implanted metallic devices including cardiac pacemakers, size limitations (weight >250 pounds), etc.
  8. Known intolerance or allergies to the MRI contrast agent (e.g. Gadolinium or Magnevist)
  9. ASA Score>2 (See "Definitions" below)
  10. Extensive scarring in an area in the path of energy planned passage to the treatment area
  11. Severe cerebrovascular disease (multiple CVA or CVA within 6 months)
  12. Patients on anti-coagulation therapy or those with an underlying bleeding disorder.
  13. Individuals who are not able or willing to tolerate the required prolonged stationary position during treatment (approximately 3 hrs.)
  14. Patient whose lesion is < 10-mm from the skin
  15. Patients with < 2-Weeks since chemotherapy
  16. Patient with < 1-Month since radiation therapy
  17. Patients with life expectancy < 6-Months
  18. Patients with surgical stabilization of tumor site with metallic hardware
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States,   Canada
 
NCT00350233
BM002
Not Provided
InSightec
InSightec
Not Provided
Principal Investigator: Christine Chung, M.D. University of California, San Diego
Principal Investigator: David Gianfelice, M.D. Toronto General Hospital
InSightec
September 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP